Cardio Diagnostics Net Worth
Cardio Diagnostics Net Worth Breakdown | CDIOW |
Cardio Diagnostics Net Worth Analysis
Cardio Diagnostics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Cardio Diagnostics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Cardio Diagnostics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Cardio Diagnostics' net worth analysis. One common approach is to calculate Cardio Diagnostics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Cardio Diagnostics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Cardio Diagnostics' net worth. This approach calculates the present value of Cardio Diagnostics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Cardio Diagnostics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Cardio Diagnostics' net worth. This involves comparing Cardio Diagnostics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Cardio Diagnostics' net worth relative to its peers.
Enterprise Value |
|
To determine if Cardio Diagnostics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cardio Diagnostics' net worth research are outlined below:
Cardio Diagnostics is way too risky over 90 days horizon | |
Cardio Diagnostics has some characteristics of a very speculative penny stock | |
Cardio Diagnostics appears to be risky and price may revert if volatility continues | |
Cardio Diagnostics has a very high chance of going through financial distress in the upcoming years | |
The company reported the revenue of 17.07 K. Net Loss for the year was (8.38 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Cardio Diagnostics generates negative cash flow from operations | |
Cardio Diagnostics has a poor financial position based on the latest SEC disclosures | |
Latest headline from news.google.com: Cardio Diagnostics shareholders approve key proposals - Investing.com |
Project Cardio Diagnostics' profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (2.13) | (2.24) | |
Return On Capital Employed | (2.00) | (2.10) | |
Return On Assets | (1.88) | (1.97) | |
Return On Equity | (2.83) | (2.97) |
When accessing Cardio Diagnostics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Cardio Diagnostics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cardio Diagnostics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Cardio Diagnostics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cardio Diagnostics Holdings. Check Cardio Diagnostics' Beneish M Score to see the likelihood of Cardio Diagnostics' management manipulating its earnings.
Evaluate Cardio Diagnostics' management efficiency
The company has return on total asset (ROA) of (0.9795) % which means that it has lost $0.9795 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.9327) %, meaning that it generated substantial loss on money invested by shareholders. Cardio Diagnostics' management efficiency ratios could be used to measure how well Cardio Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -2.24 in 2024. Return On Capital Employed is likely to drop to -2.1 in 2024. At this time, Cardio Diagnostics' Non Current Assets Total are fairly stable compared to the past year. Debt To Assets is likely to climb to 0.12 in 2024, whereas Other Current Assets are likely to drop slightly above 974.7 K in 2024.Last Reported | Projected for Next Year | ||
Book Value Per Share | 0.23 | 0.22 | |
Tangible Book Value Per Share | 0.19 | 0.18 | |
Enterprise Value Over EBITDA | (20.63) | (21.66) | |
Price Book Value Ratio | 10.68 | 10.14 | |
Enterprise Value Multiple | (20.63) | (21.66) | |
Price Fair Value | 10.68 | 10.14 | |
Enterprise Value | 31.6 M | 37.3 M |
The management team at Cardio Diagnostics has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Revenue 39.1 K | Quarterly Revenue Growth 3.562 | Revenue Per Share 0.002 | Return On Equity (2.93) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cardio Diagnostics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cardio Diagnostics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cardio Diagnostics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Levy Oded over three weeks ago Disposition of tradable shares by Levy Oded of Cardio Diagnostics subject to Rule 16b-3 | ||
Philibert Robert over two months ago Acquisition by Philibert Robert of 16000 shares of Cardio Diagnostics at 0.6 subject to Rule 16b-3 | ||
Sim Brandon over three months ago Acquisition by Sim Brandon of tradable shares of Cardio Diagnostics subject to Rule 16b-3 |
Cardio Diagnostics Earnings per Share Projection vs Actual
Cardio Diagnostics Corporate Management
Esq JD | Chief Officer | Profile | |
Timur Dogan | Chief Officer | Profile | |
Khullani JD | Vice Strategy | Profile | |
MBA JD | CFO Director | Profile | |
Khullani Abdullah | VP Strategy | Profile |
Additional Tools for Cardio Stock Analysis
When running Cardio Diagnostics' price analysis, check to measure Cardio Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardio Diagnostics is operating at the current time. Most of Cardio Diagnostics' value examination focuses on studying past and present price action to predict the probability of Cardio Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardio Diagnostics' price. Additionally, you may evaluate how the addition of Cardio Diagnostics to your portfolios can decrease your overall portfolio volatility.